Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis by Jamshidi, Sh et al.
Iranian J Parasitol: Vol. 6, No.2, 2011, pp.26-34 
 
26 
 
 
 
 
 
 
 
 
 
Original Article 
 
Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with 
Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral 
Leishmaniasis 
 
*Sh Jamshidi
1, R Avizeh
2, M Mohebali
3, S Bokaie
4 
 
1Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran 
2Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, 
Iran 
3Dept. of Medical Parasitology and Mycology, School of Public Health,
 Tehran University of Medical Sci-
ences, Tehran, Iran 
4Department of Food Hygiene, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran 
 
(Received 12 Jan 2011; accepted 25 July 2011) 
 
 
ABSTRACT 
Background: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania ma-
jor antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune 
defense mechanisms and the results were compared with standard chemotherapy meglumine 
antimoniate. 
Methods: Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection 
was carried out in 15 out of 19 dogs using L. infantum, isolated from a naturally infected poly-
symptomatic dog. 
Results: All the cases showed positive serologic results by direct agglutination test during 30-60 
days following inoculation. In the first group, which was under chemotherapy (Glucantime
R), one 
of the members showed recurrence of the disease despite rapid effect of the therapeutic protocol. 
Immunotherapy using SRL172 caused complete cleaning of the parasite in group 2, but the speed 
was less than Glucantime. Immunotherapy using L. major antigen combined with M. vaccae in 
group 3 and combine administration of immunotherapy and chemotherapy in group 4 both were 
with relapsing of one case in each group. Group 5 and 6 were consisted of positive and negative 
control dogs, respectively. 
Conclusion: Immunotherapy seems to be an adjuvant in treatment of canine leishmaniasis but it 
needs more investigation for final confirmation. 
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Introduction 
 
isceral leishmaniasis (VL), one of 
the most important chronic and 
systemic zoonosis, caused by a 
biphasic protozoan belongs to genus 
Leishmania  (1). Due to considerable dif-
ficulties in eradication of the disease, vis-
ceral leishmaniasis is one of the most impor-
tant parasitic diseases, which are endemic in 
different parts of Iran. The canidae family 
especially domestic dogs are the most 
important sources of  L. infantum infection 
for human. There is a large dog population 
in Iran (7 dogs/100 humans in Meshkin-
shahr) and rate of infection may reach to 
20% in some villages (2). Canine leishmani-
asis in dogs is more resistant to therapy than 
human leishmaniasis, and only rarely 
Leishmania organisms are eliminated with 
available drugs. Killing the symptomatic and 
seropositive dogs is obviously unacceptable 
to the owners, and it is ineffective because 
nonsymptomatic dogs and occasionally sero-
negative dogs are sources of parasite 
transmission (1). Side effects have been re-
ported following treatment with conven-
tional chemical compounds (pentavalent 
antimony) and new substitutions such as al-
lopurinol, aminosidine and antifungal drugs 
(3, 4). Although recurrence of the disease 
has also been frequent resulting in seeking 
new treatment protocols, immunotherapy as 
an efficient and alternative way can help in 
solving the problem. Gamma interferon, 
interleukin 12 and liposomal forms of some 
drugs are new treatment protocols with 
significant effect on treatment of visceral 
leishmaniasis (5, 6). 
The aim of this interventional study was to 
determine the effectiveness of immunother-
apy in experimental canine visceral 
leishmaniasis (CVL) in comparison with me-
glumine antimoniate. 
 
 
Materials and Methods 
 
Animals 
Nineteen mongrel dogs aged 1-3 years were 
used in this experiment. The dogs were 
housed in individual cages in small animal 
hospital, Veterinary Faculty of Tehran 
University. All dogs appeared healthy, as de-
termined by results of physical examination 
and normal hemogram. All of them were 
treated against internal and external para-
sites. In addition, the dogs were confirmed to 
be free of Leishmania infection using parasi-
tological and serological tests. 
 
Parasite 
A symptomatic infected dog, positive by 
both direct agglutination test (DAT) and 
ELISA against  Leishmania infection, was 
used as the donor source of the inoculum. 
During the necropsy, visceral leishmaniasis 
confirmed by observation of hepa-
tosplenomegaly as well as enlargement of 
the abdominal lymph nodes, and presence of 
the parasite confirmed by examination of 
impression smears prepared from 
lymphoproliferative organs. Using RAPD-
PCR technique the isolated parasite was 
identified as L. infantum (7).  
 
Experimental design 
Spleen from donor dog was minced to small 
cubes, macerated in Hank's balanced salt 
solution in a grinder, and dilution were made 
to provide the desired number of organisms. 
Fifteen out of 19 dogs were injected intrave-
nously with 5 ml of the spleen homogenate 
containing at least 3 × 10
5 amastigotes/ml. 
Infection of the dogs was assessed by 
collecting bone marrow aspirates, ELISA 
and DAT. These infected dogs were ran-
domly allocated into five treatment groups 
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of three dogs each. Group 1 dogs 
(Chemotherapy) were received glucantime 
(Rhone-poulenc Rorer Ltd., France) 100 
mg/kg/day, IM for 30 consecutive days. 
Group 2 dogs (Immunotherapy) were 
administered intradermaly 0.1 ml suspension 
of heat-killed M. vaccae (SRL172), 3 times 
in a month intervals containing 10 mg/ml 
bacterial protein extract. Group 3 dogs (Dual 
Immunotherapy) were injected intradermaly 
with 0.1 ml autoclaved  L. major antigen 
(ALm was prepared from the promastigotes 
of  L. major (MRHO/IR/76/ER, vaccine, 
Razi Vaccine & Serum Research Institute, 
Iran), 3 times monthly in combination with 
SRL172 as the same dose in group 2. Each 
ml of autoclaved L. major antigen contained 
3.6 mg parasite protein. Group 4 dogs 
(Immunotherapy & Chemotherapy) were in-
jected with glucantime plus L. major antigen 
and SRL172 as the same doses in groups 1 
and 3. Group 5 dogs (Positive control) were 
received sterile normal saline in a same vol-
ume as glucantime, IM, for 30 consecutive 
days. One more group comprising four dogs 
were served as negative control for evalua-
tion of environmental factors and their treat-
ment were performed as group 5. 
The animals were monitored for parasite 
establishment and subsequently for the 
development of leishmaniasis. This was 
achieved by routine screening of the dog for 
classical clinical signs, hematological and 
serological examinations for ten months af-
ter inoculation. Treatments were started two 
months after infection reconfirmed by 
serological and parasitological examinations. 
The animals were clinically examined regu-
larly each day to follow up the potential side 
effects as well as signs of infection during 
the study. Blood samples were taken before 
inoculation and at monthly intervals up to 
four months after cessation of treatment. The 
presence of specific antibodies against 
Leishmania spp. was evaluated monthly by 
DAT, using the cut off value of 1:320 and 
above (8). Doubtful results were confirmed 
by ELISA or Dipstick rK39 rapid tests (9). 
Four months after the end of treatment 
protocols, all of the animals were euthanized 
and samples of bone marrow puncture, 
spleen, and liver were prepared for parasi-
tological examinations. The mentioned sam-
ples underwent Giemsa staining followed by 
microscopic examination by light micro-
scope with high magnification (× 1000) for 
the presence of parasite. 
 
Statistical analysis 
Repeat measure one-way ANOVA test was 
performed for assess differences between he-
matological measurements and resistance or 
susceptibility to anti Leishmania therapy us-
ing SPSS software program. The influence 
of different treatment protocols on serologi-
cal and parasitological examinations was 
evaluated using Fisher exact test. Data were 
considered significant at a P value < 0.05.   
 
Results 
 
The most common clinical signs in infected 
animals were skin lesions (13 cases), 
conjunctivitis (9 cases), and enlargement of 
popliteal (15 cases) and submandibular 
lymph nodes (15 cases). Enlargement of the 
popliteal lymph nodes also happened earlier 
in the course of the study (after 48-65 days) 
in comparison with submandibular and 
prescapular lymph nodes (after 53-75 days). 
In animals that received chemotherapy, the 
signs resolved gradually after 45 days, 
Whereas, this resolution took longer in 
groups which received immunotherapy with 
adjuvant (group 2) (70 days), killed parasite 
antigen with adjuvant (group 3) (85 days) 
and immunotherapy plus chemotherapy 
(group 4) (115 days). There were no signifi-
cant changes in spleen and liver size against 
lymph nodes following treatment in different 
groups. Jamshidi et al.: Immunotherapy Using Autoclaved L. major Antigens …. 
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The most important and noticeable 
hematological changes were reduction in 
white and red blood cells (Table 2 and 3), 
PCV and hemoglobin. These factors re-
turned to their normal values following treat-
ment in groups 1 to 4. At the end of the ex-
periment, all of the factors were in normal 
ranges for every subject except one dog in 
group 1 that was probably affected by the re-
currence of clinical signs, and another one in 
group 4 that remained positive until the end 
of the experiment. All of the positive control 
animals also were shown reduction in 
hematological parameters until the end of 
study. 
Based on the serological results, 30-60 days 
following inoculation, all of the animals had 
positive titers ( ≥  1:320). Performance of 
treatment protocols changed the titers to 
negative but with varying time courses: 
group 1 (1 month), 2 (2 months), 3 and 4 (3 
months). One of the animal in group 1 
encountered increase of the serum titer in pe-
riod of follow up (4 months after cessation 
of treatment). In addition, one of the dogs in 
group 4 remained seropositive in all of the 
experiment. All of the positive control ani-
mals preserved their titers until the end of 
study and no serum titer was detected in 
negative control animals. 
Results of parasitological examination on 
liver, spleen, and bone marrow samples for 
observation of Leishman bodies are depicted 
in Table 4. Out of the animals in therapeutic 
groups of 1, 3 and 4, two cases responded to 
treatment according to parasitological re-
sults. Whereas in animals treated only with 
SRL172, no parasite was detected. Based on 
Fisher exact test in spite of decrease in para-
site population, there was no significant 
differences between groups 1, 3 and 4 with 
the control group. 
 
 
Table 1: White blood cell count changes before and following anti-Leishmania therapy in differ-
ent groups of dogs (Mean ± SE) 
 
WBC / µl   
Stages 
Groups 
Before inoculation  After infection  After cessation of 
treatment 
End of the 
study 
Group I  11300 ± 529
 s  9100 ± 230
 s  11300 ± 378  10633 ± 384
 s 
Group II  10900 ± 435
 s  8700 ± 288
 s  10900 ± 450
   10966 ± 371
  
Group III  10666 ± 554
 s  7900 ± 321
 s  10600 ± 458
   10666 ± 566
  
Group IV  11100 ± 929
 s  8600 ± 665
 s  10700 ± 550
   10700 ± 642
 s 
Group V  11466 ± 788
   8700 ± 435
   8466 ± 523
   8300 ± 642
  
Group VI  10925 ± 436
   11075 ± 526
   11125 ± 520
   11225 ± 558
  
s Significantly different (P<0.05) 
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Table 2: Red blood cell count changes before and following anti-Leishmania therapy in different 
groups of dogs (Mean ± SE) 
RBC × 10
6 /µl   
Stages 
Groups 
Before inoculation  After infection  After cessation of treatment  End of the study 
Group I  7.0 ± 0.15
 s  5.9 ± 0.21
 s  6.9 ± 0.12
   6.6 ± 0.46
 s 
Group II  7.0 ± 0.17
 s  5.9 ± 0.06
 s  7.1 ± 0.10  7.1 ± 0.06 
Group III  7.1 ± 0.17
 s  5.7 ± 0.12
 s  7.0 ± 0.12  7.0 ± 0.10
  
Group IV  7.3 ± 0.23
 s  6.0 ± 0.12
 s  7.1 ± 0.31
   7.2 ± 0.25
  
Group V  7.3 ± 0.23
   5.9 ± 0.21
   5.9 ± 0.12
   5.7 ± 0.12
  
Group VI  7.2 ± 0.14
   7.2 ± 0.13  7.2 ± 0.09
   7.3 ± 0.09
  
s Significantly different (P<0.05) 
 
 
 
 
Table 3: Observation of Leishman bodies from tissues removed at necropsy at the end of study 
 
Tissue  
Bone marrow   Liver   Spleen  
Group  
1/3   1/3   1/3
§   Group I  
0/3   0/3   0/3   Group II  
1/3   0/3   1/3   Group III  
1/3    0/3   1/3   Group IV  
3/3   3/3   3/3   Group V  
0/4   0/4   0/4   Group VI  
§ Number of positive/number of tested. 
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Table 3: Serological results (DAT=>1; 320) of experimental leishmaniasis under treatment with 
chemical and immunological procedures 
After inoculation (month)  Stage 
Before Treatment 
After in-
fection 
During 
treatment 
After treatment 
Before in-
fection 
     
Group 
Before in-
oculation 
       
    1  2  3  4  1  2  1  2  3  4 
Group I  0/3
§  3/3  3/3  3/3  3/3  1/3  0/3  0/3  0/3  0/3  1/3 
Group II  0/3  2/3  3/3  3/3  3/3  3/3  3/3  1/3  0/3  0/3  0/3 
Group III  0/3  2/3  3/3  3/3  3/3  3/3  3/3  3/3  2/3  0/3  0/3 
Group IV  0/3  1/3  3/3  3/3  3/3  3/3  3/3  3/3  3/3  1/3  1/3 
Group V  3/3  2/3  3/3  3/3  3/3  3/3  3/3  3/3  3/3  3/3  3/3 
Group VI  0/4  0/4  0/4  0/4  0/4  0/4  0/4  0/4  0/4  0/4  0/4 
§ Number of positive/number of tested 
 
Discussion 
 
In this study, experimental leishmaniasis by 
intravenous injection of spleen homogenous 
extract including amastigote form of the 
parasite was performed for the first time in 
Iran. Abranches et al. (10) used both forms 
of the parasite in experimental infection and 
indicated that amastigote form could induce 
a stronger humoral immunity and more obvi-
ous clinical signs in dogs. Up to now the 
promastigote form of the parasite, which was 
acquired from culture, has been used in ex-
perimental infection. Induction of 
experimental infection using this form of 
parasite is time consuming and rather costly 
because it must be cultured on enriched me-
dium. 
Results of chemotherapy showed that in 
spite of relatively earlier effect it was not 
complete. Although the animals became 
serologically negative (< 320) one month af-
ter treatment, infection recurred in one dog 
four months later, which was confirmed by 
parasitology. Bergeaud (11) and Melo et al. 
(12) believed that glucantime have a com-
plete effect on recovery of dogs either in 
natural or experimental cases. They did not 
mention their follow up duration. Possibly, 
in shorter period, the treatment was consid-
ered complete. However, in respect to the 
persistence of parasite in various tissues of 
affected animals, parasitological examina-
tion is highly crucial. Likewise Neogy et al. 
(13) reported that 37.5% of dogs with vis-
ceral leishmaniasis responded parasitologi-
cally to chemotherapy. 
M. vaccae had an efficient effect in treat-
ment of canine visceral leishmaniasis. Effi-
cacy of the SRL172 was confirmed previ-
ously in the treatment of tuberculosis, 
psoriasis, allergies, periodontal disorders, 
and some types of malignancies (14-16). It is 
said that this adjuvant could change immune 
pathways from antibody production (Th2) to 
cellular immunity (Th1) (17). In visceral 
leishmaniasis both types of immune re-
sponses develop and it is the balance of the 
Th1/Th2 responses that is considered impor-
tant in controlling parasite replication, disease 
progression, or a cure. The immunoglobulin 
response is usually massive in clinical forms, 
however it not a protective response and can 
eventually be detrimental. Large amounts of Iranian J Parasitol: Vol. 6, No.2, 2011, pp.26-34 
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circulating immune complexes deposition in 
the walls of blood vessels may cause vasculitis, 
polyarthritis, uveitis, and glomerulonephritis. 
There is still controversy about the effective-
ness of immunotherapy against visceral 
leishmaniasis. Whereas some reports denote 
good effects (18-20), others point some 
unresponsiveness or even worsening of the 
signs following immunotherapy (21, 22). In-
complete and slower response in dogs 
treated with killed parasite antigen combined 
with adjuvant may be related to genetic 
resistance of the involved animals, state of 
the disease or type of used antigen. In this 
study, the effectiveness of L. major antigen 
was not evaluated, hence we lack a conclu-
sive statement in this regards and it should 
be studied with more treatment groups. 
The effects of adjuvant and killed parasite 
antigen combined with glucantime (group 4) 
were also slow and incomplete. Although 
there is some reports denote reduction in 
glucantime dose or its length of use follow-
ing combination therapy (immunotherapy 
and chemotherapy) (23, 24) others report 
lack of complete response (25). In Neogy's 
study (13), which used double the dose of 
glucantime the efficacy was 100%. Failure 
of complete treatment in one of the animals 
in-group 4 may be due to the incomplete 
dose or duration of therapy, which certainly 
calls for more experiments. 
In conclusion, immunotherapy in this study 
against visceral leishmaniasis was performed 
with the aim of controlling the disease in 
dogs as one of the most important reservoirs. 
Use of M. vaccae as an adjuvant in treatment 
of canine visceral leishmaniasis is the first 
pertinent experience and primary results are 
promising. Results of the groups 3 and 4 that 
were under treatment with killed parasite 
antigen combined with adjuvant showed that 
this type of therapy can reduce the number 
of parasites in experimental form of the dis-
ease, but its favorable effects should also be 
judged in the natural form of the disease. 
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